Exploring the relationship between intestinal microbiota and immune checkpoint inhibitors in the treatment of non-small cell lung cancer: insights from the "lung and large intestine stand in exterior-interior relationship" theory

被引:0
|
作者
Li, Luwei [1 ,2 ]
Zhong, Hongmei [1 ,2 ]
Wang, Yajie [1 ,2 ]
Pan, Zongying [1 ,2 ]
Xu, Shumei [1 ,2 ]
Li, Shuai [1 ,2 ]
Zeng, Guilin [2 ]
Zhang, Weiwei [2 ]
Li, Jie [3 ]
He, Lang [2 ]
机构
[1] Chengdu Univ Tradit Chinese Med, Chengdu, Sichuan, Peoples R China
[2] Chengdu Univ Tradit Chinese Med, Chengdu Peoples Hosp 5, Canc Prevent & Treatment Inst Chengdu, Dept Oncol,Clin Med Coll 2,Affiliated Peoples Hosp, Chengdu, Peoples R China
[3] Chengdu Fifth Peoples Hosp, Ctr Med Res & Translat, Chengdu, Peoples R China
关键词
biomarkers of intestinal flora; immunotherapy; non-small cell lung cancer; TCM syndrome type; immune microenvironment; lung and large intestine; INVASIVE PULMONARY ADENOCARCINOMA; INTERNATIONAL ASSOCIATION; GUT MICROBIOME; GRADING SYSTEM; DYSBIOSIS; EPIDEMIOLOGY; EFFICACY;
D O I
10.3389/fcimb.2024.1341032
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective This study is aim to discern the Traditional Chinese Medicine (TCM) syndrome classifications relevant to immunotherapy sensitive in non-small cell lung cancer (NSCLC) patients, and to delineate intestinal microbiota biomarkers and impact that wield influence over the efficacy of NSCLC immunotherapy, grounded in the TCM theory of "lung and large intestine stand in exterior-interior relationship."Methods The study cohort consisted of patients with advanced NSCLC who received treatment at the Oncology Department of Chengdu Fifth People's Hospital. These patients were categorized into distinct TCM syndrome types and subsequently administered immune checkpoint inhibitors (ICIs), specifically PD-1 inhibitors. Stool specimens were collected from patients both prior to and following treatment. To scrutinize the differences in microbial gene sequences and species of the intestinal microbiota, 16S rRNA amplicon sequencing technology was employed. Additionally, peripheral blood samples were collected, and the analysis encompassed the assessment of T lymphocyte subsets and myeloid suppressor cell subsets via flow cytometry. Subsequently, alterations in the immune microenvironment pre- and post-treatment were thoroughly analyzed.Results The predominant clinical manifestations of advanced NSCLC patients encompassed spleen-lung Qi deficiency syndrome and Qi-Yin deficiency syndrome. Notably, the latter exhibited enhanced responsiveness to ICIs with a discernible amelioration of the immune microenvironment. Following ICIs treatment, significant variations in microbial abundance were identified among the three strains: Clostridia, Lachnospiraceae, and Lachnospirales, with a mutual dependency relationship. In the subset of patients manifesting positive PD-L1 expression and enduring therapeutic benefits, the study recorded marked increases in the ratios of CD3+%, CD4+%, and CD4+/CD8+ within the T lymphocyte subsets. Conversely, reductions were observed in the ratios of CD8%, Treg/CD4+, M-MDSC/MDSC, and G-MDSC/MDSC.Conclusion The strains Clostridia, Lachnospiraceae, and Lachnospirales emerge as potential biomarkers denoting the composition of the intestinal microbiota in the NSCLC therapy. The immunotherapy efficacy of ICIs markedly accentuates in patients displaying durable treatment benefits and those expressing positive PD-L1.
引用
收藏
页数:22
相关论文
共 50 条
  • [1] Immune checkpoint inhibitors in non-small cell lung cancer
    Eberhardt, Wilfried Ernst Erich
    ONKOLOGE, 2017, 23 (10): : 838 - 844
  • [2] Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
    Herzberg, Benjamin
    Campo, Meghan J.
    Gainor, Justin F.
    ONCOLOGIST, 2017, 22 (01): : 81 - 88
  • [3] Emerging immune checkpoint inhibitors for the treatment of non-small cell lung cancer
    Bote, Helena
    Mesas, Andres
    Baena, Javier
    Herrera, Mercedes
    Paz-Ares, Luis
    EXPERT OPINION ON EMERGING DRUGS, 2022, 27 (03) : 289 - 300
  • [4] The Relationship of Diabetes Mellitus to Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer
    Jacobi, Oded
    Landman, Yosef
    Reinhorn, Daniel
    Icht, Oded
    Sternschuss, Michal
    Rotem, Ofer
    Finkel, Inbar
    Allen, Aaron M.
    Dudnik, Elizabeth
    Goldstein, Daniel A.
    Zer, Alona
    ONCOLOGY, 2021, 99 (09) : 555 - 561
  • [5] Neoadjuvant Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer
    Xue, Chongxiang
    Dong, Huijing
    Chen, Ying
    Lu, Xingyu
    Zheng, Shuyue
    Cui, Huijuan
    JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2022, 32 (06): : 779 - 788
  • [6] Highlights on immune checkpoint inhibitors in non-small cell lung cancer
    Shen, Meng
    Ren, Xiubao
    TUMOR BIOLOGY, 2017, 39 (03)
  • [7] Immune checkpoint inhibitors in advanced non-small cell lung cancer
    Fabre, Elizabeth
    Pecuchet, Nicola
    Cadranel, Jacques
    BULLETIN DU CANCER, 2016, 103 : S138 - S143
  • [8] Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer
    Assi, Hazem I.
    Kamphorst, Alice O.
    Moukalled, Nour M.
    Ramalingam, Suresh S.
    CANCER, 2018, 124 (02) : 248 - 261
  • [9] Immune checkpoint inhibitors for the treatment of non-small cell lung cancer brain metastases
    Wei Yuxi
    Xu Yan
    Wang Mengzhao
    中华医学杂志英文版, 2023, 136 (13)
  • [10] Immune checkpoint inhibitors for the treatment of non-small cell lung cancer brain metastases
    Wei, Yuxi
    Xu, Yan
    Wang, Mengzhao
    CHINESE MEDICAL JOURNAL, 2023, 136 (13) : 1523 - 1531